Home Cart Sign in  
Chemical Structure| 13076-17-0 Chemical Structure| 13076-17-0

Structure of D(+)-LACTIDE
CAS No.: 13076-17-0

Chemical Structure| 13076-17-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Bruna L. C. Cunha ; Juliana O. Bahú ; Letícia F. Xavier ; Sara Crivellin ; Samuel D. A. de Souza ; Leandro Lodi , et al.

Abstract: Lactide dimer is an important monomer produced from lactic acid dehydration, followed by the prepolymer depolymerization process, and subsequent purification. As lactic acid is a chiral molecule, lactide can exist in three isomeric forms: L-, D-, and meso-lactide. Due to its time-consuming synthesis and the need for strict temperature and pressure control, catalyst use, low selectivity, high energy cost, and racemization, the value of a high purity lactide has a high cost in the market; moreover, little is found in scientific articles about the monomer synthesis. Lactide use is mainly for the synthesis of high molar mass poly(lactic acid) (PLA), applied as bio-based material for medical applications (e.g., prostheses and membranes), drug delivery, and hydrogels, or combined with other polymers for applications in packaging. This review elucidates the configurations and conditions of syntheses mapped for lactide production, the main properties of each of the isomeric forms, its industrial production, as well as the main applications in the market.

Keywords: applications ; industrial processes ; l-lactide ; market costs ; synthesis

Purchased from AmBeed:

Alternative Products

Product Details of [ 13076-17-0 ]

CAS No. :13076-17-0
Formula : C6H8O4
M.W : 144.13
SMILES Code : O=C([C@@H](C)O1)O[C@H](C)C1=O
MDL No. :MFCD00082566
InChI Key :JJTUDXZGHPGLLC-QWWZWVQMSA-N
Pubchem ID :5325924

Safety of [ 13076-17-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 13076-17-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 0
Fraction Csp3 0.67
Num. rotatable bonds 0
Num. H-bond acceptors 4.0
Num. H-bond donors 0.0
Molar Refractivity 31.41
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

52.6 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.21
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.64
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

-0.14
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.7
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.45

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.14
Solubility 10.5 mg/ml ; 0.073 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.32
Solubility 6.9 mg/ml ; 0.0479 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.54
Solubility 41.8 mg/ml ; 0.29 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.72 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.68
 

Historical Records

Technical Information

Categories

Similar Product of
[ 13076-17-0 ]

Chemical Structure| 4511-42-6

A357015 [4511-42-6]

(3S,6S)-3,6-Dimethyl-1,4-dioxane-2,5-dione

Reason: Optical isomers

Related Functional Groups of
[ 13076-17-0 ]

Esters

Chemical Structure| 7699-00-5

A540265 [7699-00-5]

(R)-Ethyl 2-hydroxypropanoate

Similarity: 0.89

Chemical Structure| 37555-99-0

A140176 [37555-99-0]

Diethyl 2-ethoxymalonate

Similarity: 0.87

Chemical Structure| 138-22-7

A776059 [138-22-7]

Butyl 2-hydroxypropanoate

Similarity: 0.83

Chemical Structure| 25383-99-7

A151550 [25383-99-7]

Sodium 2-((2-(stearoyloxy)propanoyl)oxy)propanoate

Similarity: 0.82

Chemical Structure| 4344-84-7

A156433 [4344-84-7]

5-Oxotetrahydrofuran-2-carboxylic acid

Similarity: 0.79

Related Parent Nucleus of
[ 13076-17-0 ]

Other Aliphatic Heterocycles

Chemical Structure| 1932281-42-9

A204487 [1932281-42-9]

(R)-1,4-Dioxane-2-carboxylic acid

Similarity: 0.83

Chemical Structure| 1821739-82-5

A406309 [1821739-82-5]

(S)-1,4-Dioxane-2-carboxylic acid

Similarity: 0.83

Chemical Structure| 60456-26-0

A290102 [60456-26-0]

(R)-Oxiran-2-ylmethyl butyrate

Similarity: 0.67

Chemical Structure| 51877-54-4

A495627 [51877-54-4]

Potassium oxirane-2-carboxylate

Similarity: 0.66

Chemical Structure| 13429-83-9

A245550 [13429-83-9]

(1S,4R)-4,7,7-Trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylic acid

Similarity: 0.64